Physician profile
Robin Park
NPI 1811558265
$946.92
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $445 · 2021: $22.76 · 2022: $84.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $353.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $236.67 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $134.48 | 2019-2021 | |
| Incyte Corporation | $84.99 | 2022 | |
| Pfizer INC. | $68.19 | 2019-2020 | |
| Viiv Healthcare Company | $42.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.75 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.